SCHEMBL2067342

SCHEMBL2067342

CCNC(=O)c1c[c]cnc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.36
CHIA Q9BZP6 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 2/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
TP53 P04637 1/20 0.34
ACVR1 Q04771 1/20 0.34
HSD17B10 Q99714 1/20 0.34
EIF2S1 P05198 1/20 0.34
EIF2AK3 Q9NZJ5 1/20 0.34
CCNE2 O96020 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
BRD4 O60885 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3515282 0.82 MAPK1 (0.43) ALDH1A1HPGDSMN1; SMN2LMNACA2
SCHEMBL2069414 0.81 PIK3C3 (0.38) LMNAEIF2S1EIF2AK3JAK2JAK1
SCHEMBL2067578 0.79 IKBKB (0.36) CSNK1DCHIAHPGDLMNACA2
SCHEMBL13973141 0.72 PRKCI (0.58) CHIAALDH1A1HPGDHSD17B10KMT2A
SCHEMBL29520153 0.72 PRKCI (0.58) CHIAALDH1A1HPGDHSD17B10KMT2A
SCHEMBL29520111 0.70 EIF2S1 (0.42) CSNK1DCA2CA4ACVR1HSD17B10
SCHEMBL6241333 0.67 ALOX15 (0.39) ALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL749356 0.67 CNR1 (0.42) SMN1; SMN2LMNAKMT2AL3MBTL1
SCHEMBL3725252 0.67 GAA (0.39) KMT2A
SCHEMBL6625604 0.66 LMNA (0.38) ALDH1A1HPGDSMN1; SMN2LMNACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 CSNK1D 71/4885CHIA 1086/4885ALDH1A1 2405/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 CSNK1D 71/4885CHIA 1086/4885ALDH1A1 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.